The Book of PeptidesThe Book of PeptidesThe Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. None of the compounds covered are approved for the uses described here by the U.S. FDA, Australia's Therapeutic Goods Administration (TGA), New Zealand's Medsafe, or the equivalent regulator in most other countries.
Most are sold for laboratory research only, a few are prescription-only drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful wherever you live. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Cross-checked against 50–100 independent sources per claim — the house standard. How this reference is checked
Reference values as published in the research record — not a recommendation, instruction, or dose suggestion for any person. Not medical advice.
No established human dose — this compound doesn't have a settled protocol yet.
Not reconstituted — vials delivery, so there's no vial to draw from.
Viking Therapeutics' dual GLP-1/GIP receptor agonist — tirzepatide's receptor pair — now in Phase 3. The 13-week Phase 2 VENTURE trial (176 participants, published in Obesity, January 2026) titrated weekly subcutaneous doses from 2.5 mg to 2.5–15 mg targets, reporting 9.1–14.7% mean weight loss against 1.7% on placebo. Viking guides Phase 3 VANQUISH data no earlier than 2027; a parallel oral tablet posted 12.2% at 13 weeks (top-line, August 2025), with 28% discontinuation across drug arms against 18% on placebo.
The member edition is the full write-up: every claim cross-checked against independent sources and challenged before print. What didn't survive the check isn't in here.